Repare Therapeutics Inc.

10/08/2021 | Press release | Distributed by Public on 10/08/2021 13:26

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 - Form 8-K